TL;DR
- •Ketamine is the fastest-acting antidepressant in published evidence — measurable mood response within 24 hours of the first dose in roughly 60-70% of treatment-resistant patients per RCTs.
- •Sublingual ketamine produces response slightly slower than IV ketamine (hours vs minutes onset) but reaches comparable response rates by the end of an induction series.
- •For SSRIs/SNRIs the timeline is 4-6 weeks at therapeutic dose; for ketamine it's hours-to-days. This is the single biggest practical difference between the mechanisms.
- •Full response typically develops over 2-3 weeks (3-6 sessions in a typical Tovani induction phase). Some patients describe rapid initial response that builds further over the first month.
- •Some patients are "non-responders" — about 30% don't reach meaningful response in standard protocols. Dose adjustment, frequency changes, and alternative approaches (IV vs sublingual) sometimes convert non-responders.
- •After the induction phase, maintenance sessions (typically monthly) sustain response. The episodic dosing model is structurally different from chronic-daily SSRI use.
Step by step
- 1
The first hours
Some patients describe mood change within hours of the first session — "lighter," "less heavy," "the depression is quieter." This is the rapid-action signature that distinguishes ketamine from SSRIs. Not all patients experience this in the first session; some respond after the second or third.
- 2
The first week
After session 1, the response often lasts 3-7 days for early responders. Session 2 (typically 2-4 days later) builds on the first. By the end of week 1, patients who are going to respond typically have a sense of "something is happening" — sleep, energy, emotional reactivity, intrusive thinking are all common change vectors.
- 3
Weeks 2-3 (induction phase)
Most patients are 3-5 sessions in by the end of week 2-3. Response typically consolidates here — the change becomes more durable between sessions. Patients describe feeling "more like themselves," fewer dark days, recovery from setbacks happening faster.
- 4
The first month
By end of month 1, response typically reaches its sustainable level. Patients on PHQ-9 / GAD-7 tracking usually see substantial score drops. The decision point: continue with maintenance dosing (monthly), step down further, or — for non-responders — pivot to dose adjustment, frequency increase, or alternative approaches.
- 5
Maintenance phase (ongoing)
Most patients move to monthly maintenance sessions to sustain response. Some can stretch to every 6-8 weeks; some need more frequent sessions during high-stress periods. The episodic pattern is sustainable long-term in most patients per current evidence.
What this actually feels like
Response to ketamine often feels qualitatively different from SSRI response. SSRIs gradually reduce depression symptom severity over months; ketamine produces a more sudden experiential shift — patients describe waking up the morning after a session and noticing depression is "quieter," "further away," or "not where it usually is." Some patients describe restoration of emotional range (being able to cry, laugh, feel love fully) as the FIRST thing they notice — before mood lift specifically. Others describe a return of energy, motivation, and forward-looking thinking. The phenomenology varies; what's consistent is the speed.
Timeline
Quick reference: hours to days for initial mood signal (first session), 2-3 weeks for response consolidation (3-6 sessions), 1 month for sustainable response. For comparison: SSRIs take 4-6 weeks to start working, 8-12 weeks for full effect. The timeline difference is the central practical advantage of ketamine over SSRIs, particularly meaningful for patients in acute distress or who can't wait 6 weeks for medication to work.
Common concerns, addressed
“What if I'm one of the non-responders?”
About 30% of treatment-resistant patients don't reach meaningful response in standard protocols per published studies. Several adjustments can convert non-responders: dose optimization (some patients need higher or lower doses), frequency changes, switching from sublingual to IV ketamine, or adding concurrent therapies. Your physician monitors response and adjusts. Non-response on standard protocols isn't the end of the conversation.
“Will the effect wear off?”
Without maintenance dosing, yes — early in treatment, response between sessions lasts 3-7 days. With maintenance (monthly sessions or your physician's individualized schedule), response sustains. The pattern is similar to other treatment-resistant interventions like TMS, where induction followed by maintenance is the standard model.
“How do I know if it's working?”
Patient-reported outcomes (PHQ-9 / GAD-7 / PCL-5 tracking before and during treatment) provide objective data. Beyond scores, look for: sleep quality, energy and motivation, emotional range, ability to do things you've been avoiding, social engagement, sense of forward momentum. Subtle changes matter — depression often lifts as a fading rather than a dramatic transition.
“I've tried 5 SSRIs. Will ketamine really work where they didn't?”
Multiple SSRI failures are exactly the strongest evidence base for ketamine. The Murrough 2013 RCT enrolled patients who had failed multiple antidepressants and showed 64% response — meaningfully higher than the 25-30% expected from another SSRI switch. The mechanism difference (NMDA/glutamate vs serotonin reuptake) is why prior failures don't predict ketamine non-response.
Who this fits best
Ketamine works fastest in patients with treatment-resistant depression of moderate-to-severe intensity, those whose depression has prominent features of hopelessness or suicidal ideation, and those who haven't responded to multiple antidepressant trials. Patients with mild-to-moderate depression who haven't yet tried first-line treatments (SSRI + therapy) typically don't need ketamine as their first option. Patients with active psychosis, severe untreated bipolar disorder, or active substance use disorder need specific protocols or alternative treatments.
Ready to start?
Tovani offers board-certified telehealth ketamine therapy for treatment-resistant depression, anxiety, PTSD, and chronic pain. Available in Florida and New Jersey.
Check eligibility5-minute screening · Reviewed by a board-certified physician · FL & NJ
Frequently asked
Will I notice change after just one session?
Some patients yes; many patients no. About 30-40% of responders feel a clear shift within hours of the first session. Others build response over 2-4 sessions. Both patterns are normal. Don't treat the first session as predictive of the full response.
How many sessions does it take to know if ketamine works for me?
Most clinicians evaluate response after 4-6 sessions over 2-3 weeks. Patients who haven't responded by then are candidates for dose adjustment, frequency increase, or alternative protocols. Don't make the "is ketamine working?" decision after 1-2 sessions; the data isn't in yet.
How is this different from SSRI timing?
SSRIs take 4-6 weeks to start working and 8-12 weeks for full effect. Ketamine works within hours-to-days for initial signal, 2-3 weeks for full response. The speed difference (hours vs weeks) is the central practical advantage and the reason ketamine is used for treatment-resistant cases where waiting for SSRIs to work isn't clinically acceptable.
Can I stay on my SSRI while doing ketamine?
Yes, in most cases. SSRIs and sublingual ketamine work through different mechanisms (serotonin reuptake vs NMDA/glutamate) and are compatible. Many patients start ketamine while still on their SSRI; some taper the SSRI later if they want to be on a single mechanism long-term.
What if I respond fast but the effect wears off between sessions?
Early in treatment, response lasting 3-7 days between sessions is normal. The induction phase builds response durability — by the end of 3-6 sessions, most patients sustain response between maintenance dosing (typically monthly). If durability isn't developing, frequency increase or dose adjustment can help.
References
- Murrough JW et al. 2013, American Journal of Psychiatry. Ketamine RCT in treatment-resistant depression — 64% response within 24 hours vs 28% placebo, establishing the rapid-action timeline. PMID 23982301
- Sanacora G et al. 2017, JAMA Psychiatry. APA consensus on ketamine in mood disorders — discusses response timelines, predictors, and protocol considerations for treatment initiation and maintenance. PMID 28249076